Background. AL-794 is an orally active prodrug of ALS-033719, which selectively inhibits the endonuclease domain of influenza virus A and B polymerase.
Influenza is a global health problem that has reached epidemic proportions, with an estimated 3 million-5 million cases of severe illness occurring annually. Influenza influences productivity, resulting in a burden on the healthcare and economic system, and is a risk for hospitalization, especially in infants and young children, elderly individuals, and people with underlying medical conditions [1, 2] . Current antiviral treatment options have the potential to reduce the severity and duration of influenza symptoms. However, these antiviral treatments, particularly neuraminidase inhibitors, are associated with a risk of drug resistance, which could overshadow their benefits and potential usefulness in more-severe cases of influenza [3] [4] [5] .
Vaccination is a cost-effective method to prevent influenza, but this approach has limitations in terms of variable efficacy, limited uptake, and cross-reactivity [6] and may not provide protection against influenza-associated hospitalization, respiratory failure, or death in elderly patients [7] . This underscores the need for an effective treatment option against a wide range of influenza virus strains.
AL-794 (also known as ALS-033794/JNJ-64155806) is an orally active, isobutyrate prodrug of ALS-033719, which selectively binds to the endonuclease domain of influenza virus polymerase acidic protein and potently inhibits the endonuclease activity [8] . ALS-033719 has an inhibitory effect on 29 influenza virus A and B strains, with 90% effective concentrations (EC 90 ) ranging from 2.3 to 267 nM [8] .
Viral challenge studies in healthy volunteers are considered valuable to evaluate the proof of concept of influenza antivirals prior to the conduct of large field-based studies [9, 10] .
This viral challenge study with AL-794 in healthy volunteers was part 4 of a multiple-part phase 1 study of AL-794 that evaluated single-and multiple-ascending doses of AL-794 for safety, tolerability, and pharmacokinetics in healthy volunteers (parts 1 and 2) and food effect (part 3). ALS-033719 has moderate (87%) protein binding in human plasma and a mean terminal elimination half-life of 6-10 hours, suggesting that 50 mg twice daily administration (under fasted conditions) is needed to maintain plasma trough concentrations above the protein-binding-adjusted EC 90 for suppression of viral replication in vitro of 41 ng/mL (101 nM). Furthermore, twice daily doses of up to 200 mg while (under fasted conditions) fasting were well tolerated [11] .
METHODS
An evaluation of the antiviral activity of AL-794 as compared to placebo in volunteers experimentally inoculated with an influenza virus (influenza A/Perth/16/2009[H3N2]) was conducted at hVIVO's quarantine unit (London, United Kingdom) between November 2015 and May 2016 (clinical trials registration NCT02588521) [12] .
Study Volunteers
The study was designed to include healthy men and women aged 18-55 years with a body mass index (calculated as the weight in kilograms divided by the height in meters squared) of 18-30. However, women of child-bearing potential were excluded because reproductive toxicity data were unavailable at the time. Subjects with contraindications to challenge with influenza virus or study procedures were excluded. Some examples of these contraindications included subjects who were immune to influenza virus (determined by an antibody titer of ≤10 hemagglutination inhibition units), immunocompromised status or diagnosis of active autoimmune disease, known allergy to constituents of influenza virus, or history of severe illness (eg, hospitalization) due to respiratory virus were excluded. Use of concomitant medications ≤14 days before the first dose of study medication was prohibited unless they were declared by the investigator and sponsor as uncompromising or noninterfering with the study objective and subject's safety.
The study was reviewed by an independent ethics committee and conducted in compliance with the Declaration of Helsinki and applicable regulatory requirements. Written informed consent was obtained from all subjects before study enrollment.
Study Design
This was a double-blinded, randomized, placebo-controlled, parallel-group, multiple-dose, viral challenge study. Subjects were screened within 56 days of influenza virus inoculation and resided in isolation in a purpose-built quarantine unit from 2 days before inoculation (day −2) until completion of dosing and procedures 11 days later (day 9). They also attended a follow-up visit 17 days (±1 day) after inoculation, followed by a completion visit 28 days (±3 days) after inoculation.
On day 0, each subject was inoculated intranasally with 1 mL of virus inoculum (approximate titer, 5.5 log 10 /mL of good manufacturing practice-grade influenza A/Perth/16/2009[H3N2]). Nasopharyngeal swab specimens were collected every 12 hours from day 2 to determine infectivity. Infection was confirmed by analyzing the nasopharyngeal swabs for influenza RNA, using a qualitative integrated cycler polymerase chain reaction (PCR) assay (Focus Diagnostics, Diasorin Molecular, Cypress, CA). Upon confirmation of infection or on day 4 regardless of PCR results, subjects were randomized within 12 hours to receive multiple doses of AL-794 as an oral suspension or placebo twice daily in fasted state for 5 days. Subjects received doses in a staggered manner so that each subject received doses at the same times each day ±5 minutes of doses administered every 12 hours, and they were closely monitored for influenza viral load and symptoms of viral infection during quarantine. Subjects were randomized 1:1 to receive 150 mg of AL-794 twice daily or placebo twice daily in cohort 1. Based on the blinded review of the data from cohort 1, patients were randomized 3:2:1 to receive 50 mg of AL-794 twice daily, 150 mg twice daily, or placebo twice daily in cohort 2. The study was designed to enroll up to 3 cohorts of 30; however, a third cohort was not evaluated, based on an assessment by the study team that sufficient data had been generated to address the main study objectives. Cohorts were combined by dose for the final analysis. The protocol did not prespecify a threshold of response prior to evaluation of doses in cohorts subsequent to cohort 1.
Study Assessments

Efficacy
Viral load parameters included evaluation of the area under the curve (AUC last ) of the influenza viral load from treatment onset through the last assessment during the period in quarantine, the peak influenza viral load after treatment onset, the time to peak influenza viral load after treatment onset, and the time from treatment onset to nondetection of influenza virus (0.4 log 10 TCID 50 /mL; Supplementary Materials).
Subjects were assessed 3 times daily throughout study period for any influenza-related symptoms and influenza severity, using an established self-reported symptom questionnaire. Symptoms captured included runny or stuffy nose, sneezing, sore throat, headache, earache, cough, shortness of breath, muscle and/or joint ache, and malaise/tiredness. Symptom levels were scored on a 0-3 scale, with 0 defined as absent, 1 defined as just noticeable, 2 defined as clearly bothersome but not preventing participation in activities, and 3 defined as quite bothersome most or all the time and preventing participation in activities.
The AUC last of total influenza symptoms from treatment onset to completion of study, the peak total symptom score, and the peak change from baseline in total influenza symptoms until checkout from the quarantine unit were calculated from the self-reported symptom scores.
The total weight of mucus produced from the time of treatment onset and the peak mucus weight after baseline were assessed (details of the methods for assessing changes in mucus weight and the related outcomes can be found in the Supplementary Materials). PCR amplification and sequencing was performed directly on nasal swab samples that showed signs of viral rebound, partial suppression, or nonresponse. The influenza virus PA gene region that encodes the endonuclease domain was also amplified and sequenced in nasal swab samples to evaluate resistance mutations to study drug. Amino acid sequences were compared with a participant's first available influenza virus-positive sample and with the reference influenza A/Perth/16/2009(H3N2) sequence. In vitro resistance selections were performed with A/Port Chalmers/1/73(H3N2) and A/California/04/2009(H1N1). The identified E119D and I38T resistance mutations caused a 52-fold shift and 88-fold shift, respectively, when introduced into a clean wild-type A/ WSN/33(H1N1) background. The resistance mutations had no effect on the viral fitness because mutations were present in virus samples cultured for 10 passages in the absence of drug pressure.
Pharmacokinetics
Blood samples were collected over 24 hours on days 1 and 5 to assess the pharmacokinetics of ALS-033719 (active form) and ALS-033927 (major inactive glucuronide metabolite) in plasma (Supplementary Table 1 ). Plasma concentrations of ALS-033719 and ALS-033927 were determined using a validated liquid chromatography tandem mass spectrometry method. The lower limit of quantification for both ALS-033719 and ALS-033927 in plasma was 1.00 ng/mL. Noncompartmental analysis (by WinNonlin 6.3; Certara, Princeton, NJ) was used to determine the pharmacokinetic parameters.
Safety
Adverse events (AEs) were evaluated by the investigator or trial staff member who was blinded to treatment assignments throughout the study period (mean duration [±SD], 28 ± 3 days). Safety assessments included clinical laboratory tests (routine hematologic testing, biochemistry analysis, coagulation analysis, and urinalysis; performed before inoculation, on postinoculation days 1, 5, and 8, at checkout, on postinoculation day 17, and on the day of study completion), physical examination (on day −1, before inoculation, on postinoculation days 0-9 and 17, and at the day of study completion), 12-lead echocardiogram (before inoculation, on postinoculation days 2-4, 6-9, and 17, and on the day of study completion), Holter monitoring, and measurement of vital signs (on day −1, before inoculation, at inoculation, on postinoculation days 0-9 and 17, and on the day of study completion).
Statistical Analysis
The intent-to-treat (ITT) population included all subjects who received the viral inoculum and at least 1 dose of study medication. The ITT infected (ITT-I) population was defined as the subset of the ITT population with a positive real-time quantitative PCR (RT-qPCR) value immediately prior to dosing or subjects who had a negative qPCR value prior to dosing but who subsequently had ≥2 positive RT-qPCR results after the first dose of study medication. The primary efficacy and pharmacokinetic analyses were performed on the ITT-I and ITT populations, respectively.
No formal hypothesis testing was included in the planned analysis. On the assumption of a 45% coefficient of variation in the AUC for viral load, inclusion of 8 infected subjects per group was estimated to provide 85% power to detect a difference of 50% in the AUC between active drug and placebo, using a 2-sided, 2-sample t test with a significance level of 5%.
The AUC last of the viral load above the limit of detection of 0.4 TCID 50 /mL was calculated using linear-linear trapezoidal summation from commencement of treatment until the subject left the facility and was analyzed using analysis of covariance with baseline viral load as a covariate and other baseline factors if predictive. Other parameters were described with descriptive statistics, using SAS statistical software, version 9.3 (Cary, NC). The results were standardized so that responses of all subjects are set from the time immediately before when they started dosing.
RESULTS
Subject Disposition and Baseline Characteristics
Of 237 subjects screened who gave written informed consent, 173 did not meet eligibility criteria, 1 declined to participate, and, owing to abnormal results of liver function tests, 2 were withdrawn before the first dose of study drug. A total of 61 subjects met the eligibility criteria and were inoculated with the influenza virus. Because of an AE, 1 subject was withdrawn prior to being randomized, leaving 60 subjects who were randomized to treatment and included in the ITT population (Supplementary Figure 1) . Of these, 42 (28 recipients of 50 mg of AL-794, 28 recipients of 150 mg of AL-794, and 14 recipients of placebo) met the definition for influenza virus infection and were included in the ITT-I population.
Demographic characteristics were similar across treatment groups (Supplementary Table 2 ). All subjects were men, with a mean age of 28.3 years, and most (87%) were white.
Efficacy
Mean baseline viral loads in the placebo group and the 50-mg and 150-mg AL-794 groups were 1.71, 2.76, and 2.11 log 10 TCID 50 /mL, respectively; mean peak viral loads were 3.72, 3.54, and 2.77 TCID 50 /mL, respectively. The analysis of viral load AUC was adjusted for differences in baseline viral load and subject weight. Both AL-794 treatments reduced the influenza viral load as compared to placebo, and 150 mg of AL-794 was more effective than 50 mg of AL-794. The difference in mean viral load AUC last was −70.0 TCID 50 /mL·h (95% confidence interval [CI] , −114 to −25.4; P = .01) for 150 mg of AL-794 versus placebo and was −39.4 TCID 50 /mL·h; 95% CI, −92.6-13.8; P = .22) for 50 mg versus placebo, corresponding to respective reductions of 53% and 37% in the AUC for viral load relative to placebo. Subjects with a lower baseline body weight showed a lower viral load AUC last (P = .04). In general, viral load showed a decreasing trend over the dosing period (0-108 hours). After the end of dosing (120-156 hours), viral load was low, and there was no evidence of rebound. Upon repeated dosing, similar results were observed (Table 1 and Figure 1A) .
In both AL-794 and placebo groups, the overall mean symptom scores were relatively low, as has been previously observed with this model. Of note, the AL-794 50-mg group had a higher baseline score. Most commonly reported symptoms were runny or stuffy nose, sneezing, sore throat, headache, earache, cough, shortness of breath, muscle and or joint ache, and malaise/ tiredness. Symptom scores showed a decreasing trend from 24 to 48 hours and continued to decrease until the end of dosing (108 hours). Scores were low (≤0.3) or 0 at 120-144 hours ( Figure 1B ) and in latter part (60-120 hours), mean scores in AL-794 treatment groups were lower than those in the placebo group. Low (≤0.3) or 0 mean scores were achieved more quickly in subjects from the 150-mg AL-794 group (60-66 hours), compared with those from the 50-mg AL-794 group (95-98 hours) and the placebo group (115-120 hours).
Mean values (±SD) of AUC symptom score, peak symptom score, and change from baseline total symptom score were lowest in the 150-mg AL-794 group, followed by the placebo and 50-mg AL-794 groups ( Table 1) 
Viral Resistance
Sequence analysis of the influenza PA gene region encoding the endonuclease domain did not detect any of the amino acid mutations associated with in vitro resistance to ALS-033719 (ie, E119D and R124K). In addition, no new mutations associated with the potential emergence of resistance to ALS-033719 were identified. A more detailed description of the viral resistance analysis will be presented elsewhere.
Pharmacokinetic Findings
On repeated dosing with 50 and 150 mg of AL-794, the mean plasma ALS-033719 AUC tau and C max increased proportionally with increasing dose level ( Table 2 ). The plasma exposure was lowest when the first dose was scheduled in the morning, whereas it was higher with the evening schedule. There was an increase in ALS-033719 exposure of up to 1.3-fold in the 50-mg AL-794 group and 1.4-fold in the 150-mg AL-794 group at steady state. Median T max of ALS-033719 was consistently observed at 2.0-3.0 hours after dosing, and the mean t 1/2 at steady state ranged from 5.32 hours after 50 mg to 6.21 hours after 150 mg ( Table 2) .
Accumulation of ALS-033719 was noted after the second dose, but no further increase in mean trough plasma concentrations Data are mean ± SD or median (range), unless otherwise indicated. The ITT-I population is defined as all subjects who were inoculated with influenza virus and received study medication (ie, the ITT population) who had a positive result of quantitative polymerase chain reaction (qPCR) analysis immediately before dosing or any volunteer who had a negative result of qPCR analysis before dosing who subsequently had ≥2 qPCR-positive values after the first dose of study medication. All subjects were in a fasted state.
Abbreviations: AUC, area under the curve; TCID, tissue culture infectious dose; VAS, visual analogue scales.
a Data are mean (95% confidence interval) and adjusted for baseline differences in viral load and subject weight. P = .22 and .01 for differences between placebo and 50 mg and 150 mg, respectively.
was noted after subsequent doses. Mean plasma concentrations after dose 9 and 10 were similar to those after dose 2, and steady state trough concentrations were achieved by dose 3 or 4 in both treatment groups. Mean plasma trough (predose) concentrations were 119-164 ng/mL for 150 mg of AL-794, which was approximately 3 times the protein-binding-adjusted in vitro EC 90 (123 ng/mL; Figure 2 ). For 50 mg of AL-794, mean trough concentrations of ALS-033719 were 50-72 ng/mL, which were at the target range of the protein-binding-adjusted in vitro EC 90 (41 ng/mL). ALS-033927 plasma concentrations generally followed the same trends as ALS-033719 at the repeated dose levels. No formal pharmacokinetics/pharmacodynamics analysis was done because the study used an attenuated virus and extrapolation to natural influenza virus infection is unknown. However, a dose-and concentration-related effect of ALS-033719 on the TCID 50 was observed. moderate in severity, except for 1 severe AE, in which the neutrophil count decreased to 0.73 × 10 9 neutrophils/L in a subject in the 150-mg AL-794 group. This subject had a single episode 10 days after his last dose, which resolved at his completion visit. The event was considered unrelated to study medication. There was no trend relating to AE frequency or severity across the 2 dose levels tested or with AL-794 as compared to placebo. There were no deaths or other serious AEs in this study. The most common AEs were hyperphosphatemia, increased alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels, increased cholesterol level, and epistaxis (Table 3) . The most commonly reported AEs considered to be drug related occurred in 12 AL-794-treated subjects (25.0%) and 4 placebo recipients (20.0%; Table 3 ). Two subjects had AEs that resulted in discontinuation of study drug. This included 1 subject who had an increased ALT level (305 IU/L) during repeated dosing with 50 mg of AL-794 and 1 who had increased ALT, amylase, AST, blood bilirubin, and lipase levels after inoculation but before receiving a dose of AL-794 or placebo. Levels in both subjects had normalized at their follow-up visits. Fever (range, 37.9°C-39.1°C) was noted in 2 subjects in the placebo group, 3 in the 50-mg (fasted) group, and 1 in the 150-mg (fasted) group. For most subjects, fever occurred 1-6 hours after the first dose. One subject did not receive dose 9 of 150 mg of AL-794, owing to prolongation of the QT interval on his predose echocardiogram. He received dose 10 as planned after his QT interval normalized. There were no notable changes in mean laboratory variables, physical examination findings, or vital signs during administration of repeated doses of study drug or placebo. The clinical efficacy outcomes in the present study indicated that both AL-794 doses had an antiviral effect as compared to placebo, particularly after adjustment for the notable differences in baseline viral load, and the data suggest that the 150-mg regimen is likely more potent than the 50-mg regimen. This finding is consistent with the observed plasma trough concentrations of ALS-033719, which were at or above the protein-bindingadjusted in vitro EC 90 with the 50-mg dose and 3-fold greater with the 150 mg dose. Further characterization of the pharmacokinetics and pharmacodynamics in a population with natural influenza virus infection are needed.
Consistent with the antiviral response, symptoms of influenza virus infection improved more quickly after treatment with 150 mg of AL-794 as compared with 50 mg of AL-794 or placebo. However, the symptom scores and mucus weights were generally low, so it is difficult to show a clear improvement over placebo treatment by using this model. Viral load was low at the end of the treatment, possibly suggesting that treatment with AL-794 did not lead to viral resistance or that the drug may have not interfered with the innate or cellular immune response to infection. Although we observed no emergence of drug-resistant viruses during this study, the sample size was relatively small for the purposes of such detection. More-definitive conclusions regarding viral resistance to AL-794/ALS-033719 should be drawn from studies in patients with natural infection.
Most adverse events reported were mild in severity, and there were no events that occurred more frequently in the AL-794 groups as compared to the placebo group. The rare occurrence of abnormal liver transaminase levels could be associated with the abnormalities caused by infection with influenza virus rather than treatment, as reported in previous influenza viral challenge studies [13] . As observed in parts 1-3 of this phase 1 study, no subjects were flagged as having potentially important clinically significant laboratory abnormalities (unpublished data)
It is clear that disease induced by the challenge influenza virus used in this study is less intense than naturally occurring infections [14] . However, previous studies showed more-severe illness with the influenza A(H3N2) virus subtypes used in this study, compared with the severity due to influenza A(H1N1) virus infections [15, 16] . Also, experimental infection of healthy volunteers provides a unique opportunity to describe the natural history and precise date of infection [17] . An important limitation of this study is the difference in baseline viral load between the 3 treatment groups. This difference may also have accounted for the higher symptom scores seen in the 50-mg AL-794 group and complicated comparison across groups. The study was conducted in cohorts, which may account for some of the differences in baseline parameters between each cohort. Additionally, the limited sample size could also be a limitation of the study. However, owing to the need for a specialized quarantine facility with a limited capacity it is only feasible to study relatively small numbers of subjects. Also, the variable rates of infection following inoculation make it difficult to plan for appropriately sized cohorts.
Overall, AL-794 was well tolerated and showed significant antiviral activity in a human influenza challenge model. Both 50 and 150 mg of AL-794 administered twice daily under fasted conditions for 5 days showed a reduction in influenza viral load greater than that observed with placebo. The safety, tolerability, and ability to achieve a plasma ALS-033719 concentration multiples greater than the protein-bindingadjusted EC 90 of AL-794 in this study support further evaluation of AL-794.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. The ITT population was defined as all subjects who received at least 1 dose of study medication and were inoculated with influenza virus. Subjects with ≥1 AE are counted once per system organ class and preferred term.
